AAV2 Vector Harboring a Liver-Restricted Promoter Facilitates Sustained Expression of Therapeutic Levels of α-Galactosidase A and the Induction of Immune Tolerance in Fabry Mice
Molecular Therapy2003Vol. 9(2), pp. 231–240
Citations Over TimeTop 10% of 2003 papers
Robin J. Ziegler, Scott Lonning, Donna Armentano, Chester Li, David W. Souza, Maribeth Cherry, C. W. Ford, Christine M. Barbon, Robert J. Desnick, Guangping Gao, James M. Wilson, Richard Peluso, Simon Godwin, Barrie J. Carter, Richard J. Gregory, Samuel C. Wadsworth, Seng H. Cheng
Related Papers
- → AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction(2020)53 cited
- → Synergy between the pharmacological chaperone 1‐deoxygalactonojirimycin and the human recombinant alpha‐galactosidase A in cultured fibroblasts from patients with Fabry disease(2011)43 cited
- → GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals(2023)14 cited
- → Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy(2020)17 cited
- → Enzyme Replacement Therapy in Patients with Fabry's Disease(2007)12 cited